App-Quantinova.ai

Secukinumab provides rapid and sustained improvement in joint tenderness and swelling in patients with PsA: 2-year results from the Phase 3 FUTURE 5 study

Iain McInnes - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

secukinumab

Secukinumab provides sustained improvement in nail psoriasis and inhibition of radiographic progression in PsA patients with nail phenotype: 52-week results from a Phase 3 study

Bruce Kirkham - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Dactylitis

secukinumab

Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?

Gareth T Jones - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Non-radiographic axial spondyloarthritis

N/A

Real-world secukinumab retention, response rates and adverse events in the treatment of PsA and axSpA

Alistair Tindell - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

secukinumab

Helping each other to deliver best practice for our axSpA patients: a special interest groups' ‘top tips’ for colleagues

William J Gregory - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

The efficacy of biologic treatment in improving fatigue in ankylosing spondylitis: a literature review and implications for clinical practice

Raj Amarnani - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

Certolizumab pegol

Continuing versus withdrawing ixekizumab in patients with PsA who achieved sustained minimal disease activity: results from the SPIRIT-P3 study

Laura C Coates - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

LY2439821

Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study

Atul Deodhar - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Dactylitis

Interleukin

Should we advocate biologic dose-reduction in patients with AxSpA?

Liz Van Rossen - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Burden of disease and relative impact of skin and joint disease on quality of life in PsA: analysis from a UK secondary care cohort

William Tillett - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Burden of psoriatic nail disease and response to biologic therapy in a PsA cohort

Preeti Nair - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

IL-4/13 inhibitor dupilumab associated with new onset peripheral axial spondyloarthritis in patients with atopic dermatitis

Catherine D Hughes - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Axial spondyloarthritis

Dupilumab

Getting the know-how: the feasibility of delivering a digital self-management programme for axSpA

Melanie J Martin - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

N/A

Physiotherapists' awareness, knowledge and confidence in screening and referral of suspected axSpA: a survey of UK clinical practice

Eliza Steen - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Longitudinal patterns of pain distribution in axSpA patients: a retrospective cohort study

Revathi Nishtala - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Comparing the visual analogue scale (VAS) and the numerical rating scale (NRS) in patient reported outcomes in PsA

Weiyu Ye - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

An analysis of short-term repeat MRI scans of vertebral corner lesions in suspected early axSpA: defining the prevalence and evolution of clinically significant spinal lesions without concurrent SIJ changes on imaging

Saion Chatterjee - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

How well are conventional DMARDs tolerated in PsA: a real-world study

Issrah Jawad - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Ustekinumab and guselkumab treatment results in differences in serum IL-17A, IL-17F and CRP levels in PsA patients: a comparison from ustekinumab Phase 3 and guselkumab Phase 2 programmes

Stefan Siebert - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Ustekinumab

Association of self-reported symptoms and behaviour in axSpA: initial analyses from the Project Nightingale study

Rosie Barnett - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

Caffeine

Filters

45280 Abstracts